Empowering Gene Editing Therapy: The Atlas of Gene Editing Enzymes from KACTUS
Overview By leveraging its sophisticated ‘Structure Aided Design and Multiplex Screening (SAMS™)’ platform, along with...
Dec 05, 2023
AccuBase™ Base Editor Enzyme: Globally In Stock Now
Overview AccuBase™ is a new generation base editing tool independently developed by Base Therapeutics with exclusive...
Dec 01, 2023
AET 2023 in the US
We will be showcasing our products and services at the Antibody Engineering & Therapeutics (AET) event...
Nov 29, 2023
The Role of Delta-like Ligand 3 (DLL3) in Targeted Therapy for Cancer
On November 13, 2023, Legend Biotech officially announced that its wholly-owned subsidiary, Legend Biotech Ireland...
Nov 27, 2023
Join KACTUS at PEGS EUROPE in Lisbon — The Epicenter of Protein & Antibody Innovation!
We're thrilled to announce our sponsorship of PEGS EUROPE, the largest protein & antibody engineering...
Nov 07, 2023
Global Release of the First Commercial Base Editor on the Market: AccuBase™
KACTUS and Base Therapeutics announced their new strategic partnership to facilitate global manufacturing and sales...
Nov 02, 2023
Join KACTUS at SITC's 38th Annual Meeting: Discovering the Latest Innovations in MHC Complexes
KACTUS is thrilled to announce our participation in the SITC's 38th Annual Meeting & Pre-Conference...
Oct 24, 2023